FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802956670> ?p ?o ?g. }

• W2802956670 abstract "The present study aimed to investigate the anticancer effect of sorafenib combined with silencing of activating transcription factor 2 (ATF2) in hepatocellular carcinoma (HCC) cells and to assess the underlying molecular mechanisms. Huh‑7 HCC cell line was selected for the present study. Small interfering RNA (siRNA)‑ATF2 sequence was constructed to silence ATF2 expression. The experiment was divided into 6 groups: i) Control; ii) vector; iii) sorafenib (6.8 µM); iv) vector+sorafenib; v) siRNA‑ATF2; and vi) siRNA‑ATF2+sorafenib groups. Cell proliferation, apoptosis, migration and invasion were detected following treatments with sorafenib and/or ATF2 silencing. Additionally, expression of tumor necrosis factor (TNF)‑α and c‑Jun N‑terminal kinase 3 (JNK3) was detected using reverse transcription‑quantitative polymerase chain reaction and western blotting. The current findings revealed that siRNA‑ATF2 significantly reduced ATF2 expression. Cell proliferation, migration and invasion abilities in the sorafenib and siRNA‑ATF2 groups were significantly reduced compared with the control group (P<0.05). Apoptotic rate in the sorafenib and siRNA‑ATF2 groups was significantly increased compared with the control group (P<0.05). The mRNA and protein expression levels of ATF2 in the sorafenib or siRNA‑ATF2 groups was significantly reduced when compared with control group. The phosphorylation of ATF2 was also reduced following sorafenib treatment or ATF2 silence. Although JNK3 mRNA expression level was not affected, the phosphorylation level of JNK3 was significantly promoted following sorafenib treatment or ATF2 silencing. Additionally, TNF‑α mRNA and protein expression levels were increased following sorafenib treatment or ATF2 silencing. It is of note that siRNA‑ATF2 treatment promoted the anticancer activity of sorafenib in Huh‑7 cells. Additionally, siRNA‑ATF2+sorafenib treatment combined additionally promoted TNF‑α expression and phosphorylation of JNK3. Combined siRNA‑ATF2 and sorafenib treatment had a greater anticancer effect compared with sorafenib or ATF2 silencing alone. The possible mechanism involved in the anticancer effect of sorafenib and ATF2 silencing may be associated with the activation of the TNF‑α/JNK3 signaling pathway." @default.
• W2802956670 created "2018-05-17" @default.
• W2802956670 creator A5045968329 @default.
• W2802956670 creator A5058435609 @default.
• W2802956670 creator A5078039491 @default.
• W2802956670 creator A5084247302 @default.
• W2802956670 creator A5088153511 @default.
• W2802956670 date "2018-04-23" @default.
• W2802956670 modified "2023-10-18" @default.
• W2802956670 title "Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells" @default.
• W2802956670 cites W1611952407 @default.
• W2802956670 cites W1632789244 @default.
• W2802956670 cites W1964249139 @default.
• W2802956670 cites W1972128179 @default.
• W2802956670 cites W1973429683 @default.
• W2802956670 cites W1974741877 @default.
• W2802956670 cites W1989892577 @default.
• W2802956670 cites W1990459924 @default.
• W2802956670 cites W2006214856 @default.
• W2802956670 cites W2022482636 @default.
• W2802956670 cites W2033882650 @default.
• W2802956670 cites W2062523121 @default.
• W2802956670 cites W2063953032 @default.
• W2802956670 cites W2081660483 @default.
• W2802956670 cites W2094058775 @default.
• W2802956670 cites W2097672870 @default.
• W2802956670 cites W2107277218 @default.
• W2802956670 cites W2111552061 @default.
• W2802956670 cites W2112310108 @default.
• W2802956670 cites W2120967735 @default.
• W2802956670 cites W2127071077 @default.
• W2802956670 cites W2176288886 @default.
• W2802956670 cites W2286119164 @default.
• W2802956670 cites W2518602763 @default.
• W2802956670 cites W2734207052 @default.
• W2802956670 cites W2746329506 @default.
• W2802956670 cites W2750632207 @default.
• W2802956670 cites W2760980960 @default.
• W2802956670 cites W2762855963 @default.
• W2802956670 cites W2766752058 @default.
• W2802956670 cites W1964184380 @default.
• W2802956670 cites W2591655368 @default.
• W2802956670 doi "https://doi.org/10.3892/mmr.2018.8921" @default.
• W2802956670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5983979" @default.
• W2802956670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29693700" @default.
• W2802956670 hasPublicationYear "2018" @default.
• W2802956670 type Work @default.
• W2802956670 sameAs 2802956670 @default.
• W2802956670 citedByCount "5" @default.
• W2802956670 countsByYear W28029566702021 @default.
• W2802956670 crossrefType "journal-article" @default.
• W2802956670 hasAuthorship W2802956670A5045968329 @default.
• W2802956670 hasAuthorship W2802956670A5058435609 @default.
• W2802956670 hasAuthorship W2802956670A5078039491 @default.
• W2802956670 hasAuthorship W2802956670A5084247302 @default.
• W2802956670 hasAuthorship W2802956670A5088153511 @default.
• W2802956670 hasBestOaLocation W28029566701 @default.
• W2802956670 hasConcept C104317684 @default.
• W2802956670 hasConcept C119056186 @default.
• W2802956670 hasConcept C1491633281 @default.
• W2802956670 hasConcept C153911025 @default.
• W2802956670 hasConcept C166703698 @default.
• W2802956670 hasConcept C185592680 @default.
• W2802956670 hasConcept C22615655 @default.
• W2802956670 hasConcept C2778019345 @default.
• W2802956670 hasConcept C2778695046 @default.
• W2802956670 hasConcept C2781018059 @default.
• W2802956670 hasConcept C29537977 @default.
• W2802956670 hasConcept C502942594 @default.
• W2802956670 hasConcept C54009773 @default.
• W2802956670 hasConcept C54355233 @default.
• W2802956670 hasConcept C55493867 @default.
• W2802956670 hasConcept C67082663 @default.
• W2802956670 hasConcept C67705224 @default.
• W2802956670 hasConcept C81885089 @default.
• W2802956670 hasConcept C86339819 @default.
• W2802956670 hasConcept C86803240 @default.
• W2802956670 hasConceptScore W2802956670C104317684 @default.
• W2802956670 hasConceptScore W2802956670C119056186 @default.
• W2802956670 hasConceptScore W2802956670C1491633281 @default.
• W2802956670 hasConceptScore W2802956670C153911025 @default.
• W2802956670 hasConceptScore W2802956670C166703698 @default.
• W2802956670 hasConceptScore W2802956670C185592680 @default.
• W2802956670 hasConceptScore W2802956670C22615655 @default.
• W2802956670 hasConceptScore W2802956670C2778019345 @default.
• W2802956670 hasConceptScore W2802956670C2778695046 @default.
• W2802956670 hasConceptScore W2802956670C2781018059 @default.
• W2802956670 hasConceptScore W2802956670C29537977 @default.
• W2802956670 hasConceptScore W2802956670C502942594 @default.
• W2802956670 hasConceptScore W2802956670C54009773 @default.
• W2802956670 hasConceptScore W2802956670C54355233 @default.
• W2802956670 hasConceptScore W2802956670C55493867 @default.
• W2802956670 hasConceptScore W2802956670C67082663 @default.
• W2802956670 hasConceptScore W2802956670C67705224 @default.
• W2802956670 hasConceptScore W2802956670C81885089 @default.
• W2802956670 hasConceptScore W2802956670C86339819 @default.
• W2802956670 hasConceptScore W2802956670C86803240 @default.
• W2802956670 hasLocation W28029566701 @default.
• W2802956670 hasLocation W28029566702 @default.
• W2802956670 hasLocation W28029566703 @default.

• next